[Surgical and non-surgical management of primary hyperparathyroidism:How do calcimimetics work?]
Primary hyperparathyroidism is a common endocrine disease. The first line therapy for the disease is surgical removal of affected parathyroid gland(s). Other therapeutic options with medication are needed to be established, because many of patients with primary hyperparathyroidism have few or no symptoms and are expected to have a long life expectancy without surgery. Cinacalcet as a calcimimetic, bisphosphonates and denosumab are promising candidates for medical management of the disease. Effectiveness and efficiency of these drugs for patients with primary hyperparathyroidism is to be evaluated in comparison with surgical treatment.
Endocrine Center, Toranomon Hospital, Tokyo, Japan.
Yasuhiro
Y
Takeuchi
D057966:Calcimimetic Agents / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000601:surgery / Q000628:therapy*; D006996:Hypocalcemia / Q000188:drug therapy; D011379:Prognosis; D011788:Quality of Life
D057966:Calcimimetic Agents